Endologix to Present at the 31st Annual J.P. Morgan Healthcare Conference

IRVINE, Calif., Jan. 3, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Event: 31st Annual J.P. Morgan Healthcare Conference

Date: Monday, January 7, 2013

Time: 9:00 a.m. PT / 12:00 p.m. ET

An audio webcast of the Company’s presentation will be available by visiting the investor relations section of Endologix’s website at www.endologix.com. A replay of the presentation will be available for 30 days.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. Endologix focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix’s website at www.endologix.com.

CONTACT: COMPANY CONTACT:

Endologix, Inc.

John McDermott, CEO

(949) 595-7200

www.endologix.com

INVESTOR CONTACTS:

The Ruth Group

Nick Laudico (646) 536-7030

Zack Kubow (646) 536-7020

Source: Endologix

News Provided by Acquire Media